Why Chromogranin A Sits at the Center of GEP-NET Surveillance
Gastroenteropancreatic neuroendocrine tumors vary widely. A grade 1 pancreatic NET may remain stable for years. A grade 3 tumor can progress within months. Because clinical symptoms often lag behind measurable biochemical change, oncology teams rely on serum biomarkers to detect disease activity between imaging cycles.
Chromogranin A (CgA) is a secretory protein released by neuroendocrine cells. When tumor burden rises, circulating CgA tends to rise with it. This makes CgA the most widely used general blood marker in NET management, referenced in European Neuroendocrine Tumor Society (ENETS) guidance and included in follow-up protocols at NET-specialist centers across Europe and North America.
Clinic teams ordering CgA today face a practical problem. The evidence base is contested, labs don't standardize the assay across institutions, and common medications elevate the marker in the absence of any tumor activity. The result is a monitoring workflow that is inconsistent, prone to false signals, and (when results are scattered across disconnected lab systems) nearly impossible to interpret as a trend rather than a snapshot.
The Guideline Divide That Complicates Clinic Operations
Two major bodies have landed in different places on CgA surveillance, and both positions carry clinical weight.
ENETS guidance describes CgA as the most practical and useful general serum tumor marker available for patients with NETs. The society recommends serial measurement as part of standard follow-up, particularly in patients with functioning tumors or those receiving peptide receptor radionuclide therapy.
The American Joint Committee on Cancer's Version 9 staging update took a notably different stance. Its authors advocate against routine serum CgA for the diagnosis and monitoring of GEP-NETs, citing limited accuracy, insufficient data quality, unclear impact on management decisions, and absence of guideline panel consensus. The AJCC v9 revision is detailed in a 2025 review of the updated staging system published in PMC.
For a clinic administrator building a standardized surveillance protocol, this divergence is an important practical issue. It directly affects how frequently labs are ordered, which values trigger clinical escalation, and how ordering clinicians document their reasoning in the chart. Without a platform-enforced standard, individual clinicians within the same practice may default to entirely different cadences.
Confounders That Inflate CgA Results
Even when a clinic establishes a consistent CgA ordering cadence, result interpretation remains complicated. Several common clinical conditions elevate serum CgA independently of tumor activity.
- Proton pump inhibitor (PPI) use: PPIs are frequently prescribed in this patient population for symptom management. They can substantially raise CgA by increasing gastric pH and stimulating enterochromaffin-like cell hyperplasia. A patient stabilized on omeprazole may show a rising CgA trend that reflects their PPI dose, not tumor growth.
- Renal impairment: Reduced glomerular filtration rate slows CgA clearance, elevating circulating levels without any change in tumor burden.
- Chronic atrophic gastritis: Destruction of parietal cells triggers reactive enterochromaffin-like cell proliferation and secondary CgA elevation.
- Systemic steroid use: Corticosteroids elevate CgA, which is relevant given the frequency of steroid use in oncology supportive care.
A review of biomarker utility in NETs available via PMC notes that no recognized international standard exists for the CgA assay. Different laboratory platforms (electrochemiluminescence, ELISA, radioimmunoassay) produce meaningfully different absolute values from the same sample. A patient transferring care between institutions may appear to have a 40% rise in CgA simply because their new lab runs a different platform.
What the CASPAR Study Tells Clinic Teams
Published in December 2024, the CASPAR study represents the most rigorous prospective validation of CgA as a surveillance biomarker in patients with carcinoid tumors. The study enrolled 153 adults and tracked serial CgA measurements alongside imaging assessments to determine how well CgA changes predicted radiological tumor progression.
The findings, available via PMC and summarized at ASCO, are instructive. Using a prespecified CgA change cutoff, the study found:
- Specificity: 93.4%
- Sensitivity: 34.4%
- Positive predictive value: 57.9%
- Negative predictive value: 84.3%
- Area under the curve: 0.73
Those numbers carry a clear operational message. A significant CgA rise, when it occurs, is highly specific: roughly 93 of 100 rising cases are true positives. Stable or falling CgA does not rule out disease progression because sensitivity is low. Approximately two-thirds of actual progressions may not show up in CgA change alone.
CASPAR's authors conclude that CgA change works best alongside imaging, not instead of it. The clinical value lies in trend tracking across multiple time points, not in any single absolute value. That conclusion has direct implications for how clinic software needs to present biomarker data.
Where the Monitoring Gaps Show Up in Practice
A review of monitoring protocols for GEP-NET patients undergoing radioligand therapy, published in PMC, highlights the coordination challenges of managing biochemical and imaging surveillance in patients on active treatment. The authors note that biochemistry, clinical assessment, and imaging need to be integrated over time - a requirement that places significant demand on clinic data infrastructure.
In practice, four gaps appear repeatedly in NET clinic operations.
- Missed draws between cycles: Clinicians often order CgA reactively (around imaging dates or at patient-initiated visits) rather than at fixed protocol intervals. This breaks the trend line and makes velocity calculations unreliable.
- No standardized interval: Without a platform-enforced schedule, clinicians within the same practice may draw CgA every 3 months or every 6 months. Retrospective trend review becomes unreliable when intervals are irregular.
- Fragmented lab data: Results arrive as PDF reports from external labs, get scanned into a document management system, and never become structured data. A clinician reviewing the chart sees a PDF instead of a trendline. The challenge of converting unstructured lab PDFs into usable clinical data is explored further in our post on AI-driven lab extraction.
- No confounder flagging: Clinicians rarely cross-check PPI status, renal function, and steroid use at the moment a CgA result is interpreted. A clinician may escalate to imaging on the basis of a PPI-driven CgA rise.
What Structured Platform Design Can Do Differently
The gap between what CgA can tell a clinician and what most clinics extract from CgA data is largely an infrastructure problem. Structured platform design closes several of these gaps without adding administrative overhead.
Rucja's Lab Intelligence layer addresses this through protocol-linked scheduling. When a GEP-NET patient's surveillance plan is entered into the portal, the system generates a biomarker draw schedule aligned to protocol milestones (rather than leaving each draw to a manual order at the next available appointment). That schedule produces evenly spaced data points across the surveillance timeline, which is the minimum requirement for meaningful trend analysis.
Lab result extraction converts incoming PDF reports into structured data, making serial CgA values available for trend visualization. A clinician reviewing a patient before a follow-up visit sees a 12-month CgA chart alongside their imaging history, rather than a stack of scanned documents. A similar approach to velocity-based biomarker trending is described in our post on AFP velocity tracking in hepatocellular carcinoma surveillance, where the operational logic transfers directly to any serial marker protocol.
The platform also surfaces active medication data alongside biomarker trends. PPI use, recent steroid courses, and current renal function values appear in the same clinical view as a rising CgA result. That context does not make the clinical decision; the clinician does. It ensures the clinician has the relevant information before deciding whether a rising CgA represents biochemical progression or a predictable confounder response.
For clinic administrators, the operational benefit is equally concrete. Protocol-linked scheduling reduces missed draws. Structured trend data supports cleaner documentation at billing and audit checkpoints. Cross-referencing CgA trend with imaging dates (displaying biochemical and radiological assessments on a unified timeline) closes the coordination gap that the radioligand therapy review identifies as a persistent challenge in active-treatment surveillance.
Consistent, structured biomarker monitoring does not change what CgA can or cannot measure. But it means that what CgA does measure is captured reliably, interpreted in context, and available as a usable trend rather than a series of isolated numbers scattered across disconnected reports. That is where the clinical value of serial monitoring is either realized or lost.
Demos take 30 minutes. We will walk you through Rucja's Lab Intelligence workflow using your clinic's actual biomarker data, including how CgA trends display alongside imaging and treatment milestones. Book a demo to see it in your practice context.